Charles Swanton

Charles Swanton

FRS FMedSci FRCP
Swanton in 2018
Born
Robert Charles Swanton

1972 (age 51–52)[2]
Poole, Dorset, England, UK[2]
EducationSt Paul's School, London
Alma materUniversity College London (MD, PhD)
AwardsEllison–Cliffe Lecture (2017)
EMBO Member (2017)
Scientific career
FieldsCancer evolution[1]
InstitutionsFrancis Crick Institute
University College London
ThesisViral cyclin disruption of mammalian cell cycle control mechanisms (1998)
Doctoral advisorNic Jones
Websitewww.crick.ac.uk/research/a-z-researchers/researchers-p-s/charles-swanton/

(Robert) Charles Swanton FRS FMedSci FRCP is British physician scientist specialising in oncology and cancer research. Swanton is a senior group leader at London's Francis Crick Institute,[3] Royal Society Napier Professor in Cancer[4] and thoracic medical oncologist at University College London[5] and University College London Hospitals,[6][7] co-director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and Chief Clinician of Cancer Research UK.[8][9]

Education

Swanton completed was educated at St Paul's School, London[2] and completed his PhD in 1999[10] at what was then the Imperial Cancer Research Fund Laboratories (now the Francis Crick Institute) and his Cancer Research UK clinician scientist/medical oncology training in 2008.[7]

Research and career

Professor Swanton speaking at a conference in 2015

Swanton combines his laboratory research with clinical duties as co-director of the CRUK Lung Cancer Centre, focussed on how tumours evolve over space and time.[7] He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome.[1][7][11][12]

Swanton is a co-founder of Achilles Therapeutics[13] with Sergio Quezada, Karl Peggs and Mark Lowdell. Achilles Therapeutics is a UCL/CRUK and Francis Crick Institute[14] biotechnology company funded by Syncona[15] that develops adoptive T cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.[citation needed]

Awards and honours

Personal life

Swanton is the son of Robert Howard Swanton (MD, FRCP) a consultant cardiologist at UCL.[23]

References

  1. ^ a b Charles Swanton publications indexed by Google Scholar
  2. ^ a b c Anon (2017). "Swanton, Prof. (Robert) Charles". Who's Who (online Oxford University Press ed.). Oxford: A & C Black. doi:10.1093/ww/9780199540884.013.U286524. (Subscription or UK public library membership required.)
  3. ^ "Charles Swanton – The Francis Crick Institute". crick.ac.uk.
  4. ^ Anon (2016). "Leading scientists awarded Royal Society Research Professorships". royalsociety.org. Royal Society. Retrieved 27 November 2018.
  5. ^ "Iris View Profile". iris.ucl.ac.uk. Archived from the original on 22 May 2017. Retrieved 12 January 2022.
  6. ^ "The UCLH lung cancer service". uclh.nhs.uk. Retrieved 27 November 2018.
  7. ^ a b c d e f Anon (2018). "Professor Charles Swanton FMedSci FRS". London: Royal Society. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    "All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." --"Terms, conditions and policies | Royal Society". Archived from the original on 11 November 2016. Retrieved 27 June 2018.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  8. ^ "Chief Executive and Executive Board". 27 September 2013.
  9. ^ Charles Swanton publications from Europe PubMed Central
  10. ^ Swanton, Robert Charles (1998). Viral cyclin disruption of mammalian cell cycle control mechanisms. london.ac.uk (PhD thesis). University College London (University of London). OCLC 941060556. EThOS uk.bl.ethos.286205.
  11. ^ Swanton, Charles; Mann, David J.; Fleckenstein, Bernhard; Neipel, Frank; Peters, Gordon; Jones, Nic (1997). "Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins". Nature. 390 (6656): 184–187. Bibcode:1997Natur.390..184S. doi:10.1038/36606. ISSN 0028-0836. PMID 9367157. S2CID 4397584.
  12. ^ Charles Swanton publications indexed by the Scopus bibliographic database. (subscription required)
  13. ^ "Our Team – Achilles Therapeutics". achillestx.com. Retrieved 27 November 2018.
  14. ^ UCL (5 October 2016). "UCL spin-out Achilles Therapeutics to develop immunotherapies for cancer". UCL News. Retrieved 27 November 2018.
  15. ^ "Achilles Therapeutics". Syncona. Retrieved 27 November 2018.
  16. ^ "Pontecorvo Prize for best PhD thesis". cancerresearchuk.org. 28 October 2015. Retrieved 27 November 2018.
  17. ^ "Professor Charles Swanton – The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 27 November 2018.
  18. ^ Systems, eZ. "List of Award Winners / Fondazione San Salvatore". fondazionesansalvatore.ch. Archived from the original on 22 July 2018. Retrieved 27 November 2018.
  19. ^ "Translational Cancer Research Prize". cancerresearchuk.org. 28 October 2015. Retrieved 27 November 2018.
  20. ^ Jukic, Igor. "EMBO welcomes 65 new members". Embo.org. Archived from the original on 27 September 2017. Retrieved 27 November 2018.
  21. ^ "Kraft Prize Symposium – Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 27 November 2018.
  22. ^ Azvolinsky, Anna (2018). "Cancer Evolutionist: A Profile of Charles Swanton". The Scientist.
  23. ^ Anon (2017). "Swanton, Robert Howard". Who's Who (online Oxford University Press ed.). Oxford: A & C Black. doi:10.1093/ww/9780199540884.013.U4000216. (Subscription or UK public library membership required.)

 This article incorporates text available under the CC BY 4.0 license.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Charles_Swanton&oldid=1202143721"